scholarly journals Bone Health in Men with Prostate Cancer: Review Article

2019 ◽  
Vol 17 (6) ◽  
pp. 527-537 ◽  
Author(s):  
Salma A M El Badri ◽  
Abdulazeez Salawu ◽  
Janet E Brown
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Bone Health ◽  
Cancer Survival ◽  
Cancer Treatments ◽  
Cumulative Impact ◽  
Cancer Review ◽  
Published Evidence ◽  
Prostate Cancer Treatments ◽  
The Impact

Abstract Purpose of Review The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. Recent Findings The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. Summary It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health.

scholarly journals Sexual dysfunction associated with prostate cancer treatment in Japanese men: a qualitative research

2022 ◽  
Author(s):  
Saeko Hayashi ◽  
Fumiko Oishi ◽  
Kazuki Sato ◽  
Hiromi Fukuda ◽  
Shoko Ando
Keyword(s):  
Prostate Cancer ◽  
Sexual Dysfunction ◽  
Cancer Treatment ◽  
External Beam Radiotherapy ◽  
Structured Interviews ◽  
Cancer Treatments ◽  
Prostate Cancer Treatment ◽  
Good Reliability ◽  
Japanese Men ◽  
Prostate Cancer Treatments

Abstract Purpose We investigated the experiences of Japanese men with sexual dysfunction associated with various prostate cancer treatments. Methods We included 38 Japanese men who underwent the following initial treatments for prostate cancer: radical prostatectomy (n = 10), external beam radiotherapy (n = 12), brachytherapy (n = 5), and androgen deprivation therapy (n = 11). Semi-structured interviews were conducted regarding sexual dysfunction associated with prostate cancer treatment. Data were analyzed using a content analysis method. To obtain a unique experience for each treatment, we confirmed and organized the treatment method from which the code that constituted each category was derived. The category reliability was calculated based on Scott’s formula for the matching rate of the classification by three qualitative researchers. The criterion for good reliability was set at 70%. Results Japanese men with sexual dysfunction associated with prostate cancer treatments experienced the following: a desire to maintain sexual function and conflict in decision-making concerning the initial treatment for prostate cancer; a loss of values related to sexual dysfunction; an uncertainty regarding the consequences of sexual dysfunction; a sense of calm with fewer adverse effects of sexual dysfunction at the early treatment stage; an effort to accept sexual dysfunction; and management of their changed body at the later treatment stages. The concordance rates for the categories were 70% and 78%. Additionally, there were glimpses of experiences common to all treatments and trends in treatment-specific experiences. Conclusion It is necessary to provide care based on the experience of Japanese men with sexual dysfunction after prostate cancer treatment.

scholarly journals Causal inference in continuous time: an example on prostate cancer therapy

Biostatistics ◽  
2018 ◽  
Vol 21 (1) ◽  
pp. 172-185 ◽  
Author(s):  
Pål Christie Ryalen ◽  
Mats Julius Stensrud ◽  
Sophie Fosså ◽  
Kjetil Røysland
Keyword(s):  
Prostate Cancer ◽  
Continuous Time ◽  
Causal Effect ◽  
Structural Models ◽  
Marginal Structural Models ◽  
Cancer Treatments ◽  
Discrete Parameter ◽  
Inverse Probability Weights ◽  
Using Data ◽  
Prostate Cancer Treatments

Abstract In marginal structural models (MSMs), time is traditionally treated as a discrete parameter. In survival analysis on the other hand, we study processes that develop in continuous time. Therefore, Røysland (2011. A martingale approach to continuous-time marginal structural models. Bernoulli 17, 895–915) developed the continuous-time MSMs, along with continuous-time weights. The continuous-time weights are conceptually similar to the inverse probability weights that are used in discrete time MSMs. Here, we demonstrate that continuous-time MSMs may be used in practice. First, we briefly describe the causal model assumptions using counting process notation, and we suggest how causal effect estimates can be derived by calculating continuous-time weights. Then, we describe how additive hazard models can be used to find such effect estimates. Finally, we apply this strategy to compare medium to long-term differences between the two prostate cancer treatments radical prostatectomy and radiation therapy, using data from the Norwegian Cancer Registry. In contrast to the results of a naive analysis, we find that the marginal cumulative incidence of treatment failure is similar between the strategies, accounting for the competing risk of other death.

The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment

2009 ◽  
Vol 185 (6) ◽  
pp. 397-403 ◽  
Author(s):  
Markus Karl Alfred Herrmann ◽  
Tammo Gsänger ◽  
Arne Strauss ◽  
Tereza Kertesz ◽  
Hendrik A. Wolff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Prostate Volume ◽  
External Beam ◽  
Hdr Brachytherapy ◽  
Beam Irradiation ◽  
Volume Changes ◽  
Prostate Cancer Treatment ◽  
External Beam Irradiation ◽  
The Impact

Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with metastatic prostate cancer: A real-world, population-based study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17056-e17056
Author(s):  
Atul Batra ◽  
Shiying Kong ◽  
Winson Y. Cheung
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Population Based ◽  
Treatment Patterns ◽  
Survival Outcomes ◽  
Administrative Claims ◽  
World Population ◽  
Cancer Treatments ◽  
Lower Likelihood ◽  
The Impact

e17056 Background: Prior cardio-oncology research has focused on examining the future risk of CVD as a result of cancer treatments. The impact of pre-existing CVD on cancer treatments is less clear. This study aimed to identify the associations of baseline CVD on treatment patterns and survival outcomes in metastatic prostate cancer where older age and exposure to androgen deprivation therapy can potentiate cardiac risks. Methods: We identified all patients diagnosed with metastatic prostate cancer in a large Canadian province from 2004 to 2017 using the population-based cancer registry. Administrative claims were linked to ascertain any diagnoses of pre-existing CVD, defined as any of arrythmias [AR], cerebrovascular accidents [CVAs], myocardial infarctions [MIs], or congestive heart failure [CHF] that preceded the diagnosis of metastatic prostate cancer. Logistic and Cox regression models were constructed to determine the associations of baseline CVD with receipt of cancer treatments (such as radiation, or systemic therapy) and overall survival (OS). Results: A total of 3,257 patients were included. The median age was 66 years (interquartile range, 46-95 years). At diagnosis of advanced prostate cancer, 993 (30.5%) had pre-existing CVD: 10.0% AR, 4.3% CVAs, 3.0% MIs, 2.8% CHF and 10.4% multiple CVDs. The Charlson comorbidity index (CCI) was 0, 1 and >1 in 53.4%, 27.3% and 19.3%, respectively. Overall, 2078 (63.8%) patients received chemotherapy, while 747 (22.9%) received radiotherapy. After adjusting for age and CCI, pre-existing CVD was associated with a lower likelihood of chemotherapy (odds ratio [OR], 0.67; 95% confidence interval [CI], 0.61-0.75; P=0.001) and radiotherapy (OR, 0.87; 95% CI, 0.85-0.91; P<0.001). Likewise, CVD was associated with worse OS, after adjusting for measured confounding variables (see table). Conclusions: One-third of patients with metastatic prostate cancer had pre-existing CVD, which was associated with a lower likelihood of chemotherapy and worse OS. In the context of an aging general population, early cardio-oncology consultations to optimize CVD management may lead to safer and broader uptake of appropriate prostate cancer treatments.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document